Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
18 May 2017
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
The promising results from a clinical trial developed and run by investigators at Melanoma Institute Australia are being presented in Chicago at the world’s largest oncology conference, the American Society of Clinical Oncology (ASCO) Annual Meeting, attended by more than 30,000 delegates from around the world.
The ground-breaking Anti-PD1 Brain Collaboration (ABC) clinical trial involved advanced melanoma patients being given a combination of two different immunotherapy drugs: nivolumab (Opdivo®) and ipilimumab (Yervoy®).
Results from an early analysis of this trial show 79% of advanced melanoma patients with brain metastases treated with the combination immunotherapy were still alive at six months. 66% of those who got nivolumab alone were also alive after six months.
Typically, patients with active brain metastases survive only four to five months and never even used to be admitted to clinical trials because their prognosis was so dire.
“This is an absolute game-changer for how we treat patients with advanced melanoma which has spread to the brain. It provides new hope to the 1,800 Australians expected to die from melanoma this year,” said Professor Georgina Long, the study’s chief investigator, Conjoint Medical Director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research at The University of Sydney.
“Quite simply, having brain metastases is no longer a death sentence,” she said. “We can now offer additional years of life and also the hope of ultimately beating this disease to a significant number of people.”
In February 2016, Australia approved the use of nivolumab for advanced melanoma patients as a stand-alone treatment or in combination with ipilimumab.
However, patients with brain metastases were excluded from previous clinical trials, including the ones that led to the drugs’ approval. This was what prompted Melanoma Institute Australia to develop and run the world-first ABC trial.
“I have melanoma patients with brain metastases who would not be alive today if they had not participated in this trial,” Professor Long said.
The study also examined patients who had no previous drug therapy prior to joining the trial, and those who received previous targeted drug therapy which is effective in patients with BRAF mutations in their melanoma.
It found that the combination of nivolumab and ipilimumab was more active in patients who had not received prior targeted BRAF-directed drug therapy.
Under the current Pharmaceutical Benefits Scheme (PBS) in Australia, doctors are restricted in the order in which they can prescribe the targeted BRAF-directed drug therapies and immunotherapy as treatments for melanoma. The restrictions make it very difficult to give immunotherapy first to patients who have the BRAF mutation in their melanoma (approximately 40% of all melanoma patients).
However, this new research strongly suggests that immunotherapy should be the first-line treatment in suitable patients, in particular, those with brain metastases.
Young dad, Leigh Miller (pictured here), is just one of the patients on the ABC Trial who has had a remarkable turnaround.
It's time to outlaw sunburn on reality TV shows - enough is enough
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Identifying markers for optimal response
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
Global Melanoma Research Report - July
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
A day in the life of... Sarah Lane
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Differentiating moles from melanoma
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
Introducing SunSense Sunscreen
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
60 Minutes' MIA Patient Feature Program
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Training our future melanoma experts
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Update from ASCO 2017
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
Diagnosing melanoma of the mouth
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New practice-changing research will reduce the need for major surgery in many melanoma patients
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
MIA researchers to share new findings at world's largest cancer conference
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 wraps up!
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Melanoma March 2017 helping kick start the Big Data for Melanoma national Research Project!
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
Whole genome sequencing finds unexpected genomic landscape in melanoma
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
Shining a light on melanomas that aren't caused by the sun
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.
New research which more accurately predicts survival for melanoma patients
Using MIA's patient database, researchers have developed conditional survival estimates for Stage III melanoma patients to more accurately predict survival outcomes.
Celebrating 60 Years of melanoma research to save lives
MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.